Regen BioPharma Inc (RGBP)

Name: Regen BioPharma Inc (RGBP) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Also trades as RGBPP. Every security a company lists rests on one set of financial statements, so these figures cover the whole company.

Build a valuation ↗↓ Download CSV

CIK 0001589150 · OTC · Pharmaceutical Preparations

Sector Manufacturing
Incorporated NV
Fiscal year ends Sep 30

For the year ended 2025-09-30, Regen BioPharma Inc reported revenue of $236.6K. Over the twelve months to 2026-06-30, revenue was $236.6K.

Key ratios (year ended 2025-09-30)

-143.1%

Operating margin

-538.8%

Net margin

0.0%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 10-Q (quarterly report) · 2026-08-17

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-09-30	2024-09-30	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31
Revenue	$236.6K	$236.6K	$236.6K	$236.6K	n/a	n/a	n/a	n/a	n/a	n/a	n/a
R&D Expense	$223.9K	$11.7K	$153.7K	$212.3K	n/a	n/a	n/a	$158.1K	n/a	n/a	n/a
Operating Income	-$803.9K	-$338.5K	-$417.2K	-$687.0K	n/a	n/a	n/a	-$339.6K	n/a	n/a	n/a
Net Income	-$1.19M	-$1.27M	-$668.3K	$1.16M	n/a	n/a	n/a	$2.44M	n/a	n/a	n/a
EPS (Diluted)	n/a	-$0.05	-$0.16	$0.29	n/a	n/a	n/a	$0.71	n/a	n/a	n/a
Total Assets	$287.6K	$274.6K	$161.1K	$353.6K	n/a	n/a	n/a	$559.0K	n/a	n/a	n/a
Total Liabilities	$6.17M	$6.56M	$5.38M	$5.46M	n/a	n/a	n/a	$8.60M	n/a	n/a	n/a
Shareholders' Equity	-$5.88M	-$6.28M	-$5.22M	-$5.10M	-$5.03M	-$4.93M	-$4.88M	-$8.04M	-$8.35M	-$76.75M	-$9.76M
Cash & Equivalents	$239	$69.6K	$716	$121.0K	n/a	n/a	n/a	$51.2K	n/a	n/a	n/a
Operating Cash Flow	-$445.2K	-$383.6K	-$751.5K	-$173.9K	n/a	n/a	n/a	-$606.9K	n/a	n/a	n/a
Shares Outstanding	1.13B	39.37M	5.26M	3.51M	n/a	n/a	n/a	3.35M	n/a	n/a	n/a
Weighted Average Diluted Shares	n/a	23.52M	4.11M	3.54M	n/a	n/a	n/a	3.14M	n/a	n/a	n/a
EPS (Basic)	n/a	-$0.05	-$0.16	$0.29	n/a	n/a	n/a	$0.71	n/a	n/a	n/a